4.7 Article

Mycoepoxydiene, a fungal polyketide inhibits MCF-7 cells through simultaneously targeting p53 and NF-κB pathways

期刊

BIOCHEMICAL PHARMACOLOGY
卷 84, 期 7, 页码 891-899

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2012.07.004

关键词

Mycoepoxydiene; Polyketide; ROS; p53; NF-kappa B

资金

  1. 973 Programs [2010CB833802, 2012CB721005]
  2. NSFC [90913024, 31028019]
  3. National Science Fund for Distinguished Young Scholars [30325044]

向作者/读者索取更多资源

Mycoepoxydiene (MED) is a cytotoxic polyketide that is isolated from the marine fungal strain Diaporthe sp. HLY-1, which is associated with mangroves: however, the mechanism of action of MED remains unknown. Here, we report the molecular mechanisms of apoptosis activation and growth inhibition induced by MED in MCF-7 cells. The present results show that MED induces DNA damage through the production of reactive oxygen species (ROS), which resulted in the phosphorylation of H2AX and the activation of the Ataxia telangiectasia mutated kinase (ATM) and p53 signaling pathways. In addition, MED increases the accumulation of I kappa B alpha and enhances the association between IKK gamma and Hsp27 via the activation of Hsp27, which eventually resulted in the inhibition of TNF-alpha-induced NF-kappa B transactivation. Therefore, we conclude that MED inhibits MCF-7 cells by simultaneously activating p53 to induce apoptosis and suppressing NF-kappa B to disrupt cell proliferation. Because small molecules having both of these effects are rare, further exploration of MED as an antitumor lead compound is needed. (C) 2012 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation

Jifeng Wang, Zhenyu Li, Zhiyuan Lin, Baobing Zhao, Yang Wang, Ruixian Peng, Meifang Wang, Chunhua Lu, Guowei Shi, Yuemao Shen

CANCER LETTERS (2015)

Article Medicine, Research & Experimental

17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition

Zhiyuan Lin, Ruixian Peng, Zhenyu Li, Yang Wang, Chunhua Lu, Yuemao Shen, Jifeng Wang, Guowei Shi

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2015)

Article Agriculture, Multidisciplinary

New Apoptosis-Inducing Sesquiterpenoids from the Mycelial Culture of Chinese Edible Fungus Pleurotus cystidiosus

Yongbiao Zheng, Haiyue Pang, Jifeng Wang, Guowei Shi, Jianzhong Huang

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2015)

Article Oncology

Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer

Shanna A. Arnold Egloff, Liping Du, Holli A. Loomans, Alina Starchenko, Pei-Fang Su, Tatiana Ketova, Paul B. Knoll, Jifeng Wang, Ahmed Q. Haddad, Oluwole Fadare, Justin M. Cates, Yair Lotan, Yu Shyr, Peter E. Clark, Andries Zijlstra

ONCOTARGET (2017)

Article Plant Sciences

Gunnilactams A-C, Macrocyclic Tetralactams from the Mycelial Culture of the Entomogenous Fungus Paecilomyces gunnii

Yongbiao Zheng, Jiyan Zhang, Liufeng Wei, Mianmian Shi, Jifeng Wang, Jianzhong Huang

JOURNAL OF NATURAL PRODUCTS (2017)

Article Oncology

Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein

Jun Zhang, Xilong Wang, Yangyun Wang, Ruixian Peng, Zhiyuan Lin, Yang Wang, Bo Hu, Jifeng Wang, Guowei Shi

ONCOLOGY LETTERS (2017)

Article Oncology

Transcription factor KLF13 inhibits AKT activation and suppresses the growth of prostate carcinoma cells

Qiang Wang, Ruixian Peng, Boshi Wang, Jifeng Wang, Wandong Yu, Yongzhong Liu, Guowei Shi

CANCER BIOMARKERS (2018)

Article Oncology

Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in over 140,000 European Descendants

Lang Wu, Jifeng Wang, Qiuyin Cai, Taylor B. Cavazos, Nima C. Emami, Jirong Long, Xiao-Ou Shu, Yingchang Lu, Xingyi Guo, Joshua A. Bauer, Bogdan Pasaniuc, Kathryn L. Penney, Matthew L. Freedman, Zsofia Kote-Jarai, John S. Witte, Christopher A. Haiman, Rosalind A. Eeles, Wei Zheng, Sara Benlloch, Brian E. Henderson, David Conti, Fredrick R. Schumacher, Douglas Easton, Ali Amin Al Olama, Kenneth Muir, Sonja Berndt, Stephen Chanock, Demetrius Albanes, Stephanie Weinstein, Stella Koutros, Fredrik Wildund, Henrik Gronberg, Susan M. Gapstur, Victoria L. Stevens, Catherine M. Tangen, Jyotsna Batra, Judith Clements, Nora Pashayan, Johanna Schleutker, Alicia Wolk, Catharine West, Lorelei Mucci, Geraldine Cancel-Tassin, Karina Dalsgaard Sorensen, Eli Marie Grindedal, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan, Ruth C. Travis, Robert J. Hamilton, Bany S. Rosenstein, Yong-Jie Lu, Graham G. Giles, Adam S. Kibel, Ana Vega, Manolis Kogevinas, Jong Y. Park, Janet L. Stanford, Lisa F. Newcomb, Cezary Cybulski, Borge G. Nordestgaard, Hermann Brenner, Christian Maier, Jeri Kim, Esther M. John, Manuel R. Teixeira, Susan L. Neuhausen, Kim De Ruyck, Azad Razack, Marija Gamulin, Radka Kaneva, Nawaid Usmani, Frank Claessens, Paul A. Townsend, Manuela Gago Dominguez, Monique J. Roobol, Florence Menegaux, Kay-Tee Khaw, Lisa Cannon-Albright, Stephen N. Thibodeau, David J. Hunter, William J. Blot, Elio Riboli

CANCER RESEARCH (2019)

Article Oncology

The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells

Ruixian Peng, Zhenyu Li, Zhiyuan Lin, Yang Wang, Wei Wang, Bo Hu, Xilong Wang, Jun Zhang, Yangyun Wang, Renyuan Zhou, Chunhua Lu, Yuemao Shen, Jifeng Wang, Guowei Shi

AMERICAN JOURNAL OF CANCER RESEARCH (2015)

Article Pharmacology & Pharmacy

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib

Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci

Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Cardiac human bitter taste receptors contain naturally occurring variants that alter function

Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas

Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li

Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.

BIOCHEMICAL PHARMACOLOGY (2024)

Review Pharmacology & Pharmacy

Ferroptosis resistance in cancer: recent advances and future perspectives

Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang

Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.

BIOCHEMICAL PHARMACOLOGY (2024)